



Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative Vaccine Development and Vaccine Adjuvant Technologies

Guest Editors:

Dr. Ahmed Mostafa

Center of Scientific Excellence for
Influenza Viruses, National
Research Centre, 12622 Giza,
Egypt

Dr. Mobarak Abu Mraheil

Giessen Institute for Medical
Microbiology, Justus-Liebig
University, 35392 Giessen,
Germany

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

Newly emerging and reemerging infectious pathogens, especially the unprecedented viral epidemics and pandemics, have threatened animals and humans. Several interlaced and synergistic factors could accelerate the emergence and spread of these life-threatening pathogens in hosts such as animal and/or human populations. Due to the limited antimicrobial options against emerging and reemerging infectious pathogens and the rapid development of drug-resistant strains following uncontrolled implementation of these medications to infected animals, the vaccination and cell-based immunostimulatory therapies remain pivotal options against these infectious pathogens in both animal and human populations. Therefore, in this issue, we are interested in receiving manuscripts for studies with innovative findings in the following topics:

1. Immunization against emerging infectious diseases;
2. Immunotherapy against emerging infectious diseases;
3. Challenges to current vaccination strategies;
4. Innovative vaccine development (new-generation) technologies;
5. Novel vaccine adjuvant technologies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com